Clinical Trial of the Use of Ketamine in Treatment Resistant Depression

  • STATUS
    Not Recruiting
  • participants needed
    20
  • sponsor
    National Institute of Neurology and Neurosurgery, Mexico
Updated on 21 January 2021
Investigator
Rodrigo Pérez-Esparza, MD
Primary Contact
National Institute of Neurology and Neurosurgery (2.4 mi away) Contact
ketamine

Summary

The purpose of this study is to determine the efficacy of the use of intravenous low-dose ketamine in the treatment of treatment-resistant depression (TRD), as well as the changes in Glutamate neurotransmission and inflammatory serum markers.

Description

The purpose of this study is to determine the efficacy of the use of intravenous low-dose ketamine (0.5 mg/kg) in the treatment of treatment-resistant depression (TRD), as well as the changes in Glutamate neurotransmission measured by Magnetic Resonance Imaging Spectroscopy and inflammatory serum markers (IL-6, TNF-alpha).

Details
Condition Depressive Disorder, Treatment-Resistant
Treatment Ketamine
Clinical Study IdentifierNCT02610712
SponsorNational Institute of Neurology and Neurosurgery, Mexico
Last Modified on21 January 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note